HAYWARD, Calif., Nov. 1, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, today announced that it will be presenting data on arhalofenate, a potential best-in-class treatment for gout, at the 2011 ACR/AHP Annual Scientific Meeting onWednesday, November 9, 2011 in Chicago, IL. The presentation will describe the results of a pooled analysis of four Phase 2 studies in patients with type 2 diabetes, a subset of which exhibited hyperuricemia. The analysis shows that the patients experienced statistically and clinically significant reductions in serum uric acid that were fully retained in patients with mild-to-moderate renal insufficiency.
Presentation Title: "Arhalofenate, a Potential Novel Treatment for Hyperuricemia, with or without Metabolic Co-Morbidities, in Patients with Gout: Meta-Analysis of Urate Lowering in Four Phase 2 Studies in Type 2 Diabetes"
Session Title: Metabolic and Crystal Arthropathies II: Concurrent Session on the Anti-Gout Medications – Dosing, Adverse Effects, and Economic Burden
Date/Time: Wednesday, November 9, 2011 from 10:15 AM - 10:30 AM CST
Location: McCormick Place Convention Center: W 474 A
About Hyperuricemia and Gout
Gout is a chronic, progressive rheumatic disease, caused by an inflammatory response to uric acid crystals deposited in joints and soft tissues as a result of excess uric acid in the blood (hyperuricemia). Elevated sUA levels cause urate crystals for form in joints triggering acute arthritic flares, chronic destructive arthropathy and formation of tophi. According to the NHANES (2007-2008) study, the incidence of hyperuricemia in the US is over 45 million and over 8 million have progressed to a gout diagnosis.
Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases. The company has three clinical-stage compounds: arhalofenate, which has completed four Phase 2 trials and is currently conducting three Phase 2b trials for gout; MBX-2982, which has recently completed a Phase 2a trial in patients with Type 2 diabetes; and MBX-8025, which has completed a Phase 2 trial in patients with dyslipidemia.
For additional information about Metabolex and its development pipeline, visit www.metabolex.com.
SOURCE Metabolex, Inc.